Topiramate (Qudexy XR) vs Topiramate (Topamax Sprinkle)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Epilepsy
Shared mechanism: Voltage-gated sodium channels; GABA-A receptor; AMPA/kainate glutamate receptors; carbonic anhydrase · full Epilepsy pipeline
Topiramate (Qudexy XR)
Marketed by Upsher-Smith Laboratories, LLC
NCT01142193 · Phase 3 · completed
This was a randomized, double-blind, placebo-controlled trial of 249 participants. The primary clinical endpoint—percent reduction in weekly partial-onset seizure frequency over 11 weeks—was met, with a statistically significant advantage for USL255 over placebo (p<0.001).
Reported efficacy
Percent Reduction From Baseline in Weekly (7 Day) Partial-onset Seizure Frequency During the Titration Plus Maintenance Phase Compared to Baseline. (11 weeks): Percent Reduction From Baseline in Weekly (7 Day) Partial-onset Seizure Frequency During the Titration Plus Maintenance Phase Compared to Baseline. (11 weeks): USL255 39.5 Percent Reduction (range -227.3 to 100) | Placebo 21.65 Percent Reduction (range -531.2 to 100) (met)
Result source: NCT01142193
Topiramate (Topamax Sprinkle)
Marketed by Johnson & Johnson
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
Results for Epilepsy
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Topiramate (Qudexy XR) | Topiramate (Topamax Sprinkle) |
|---|---|---|
| Seizure frequency, % change | —Not posted · NCT00236717 | —Not reported |
| 50% responder rate | 33.9% vs 17.6%+16.3 vs placeboNCT01142193 | —Not reported |
| Seizure freedom | —Not posted · NCT00236717 | —Not reported |
Seizure frequency, % change
- Topiramate (Qudexy XR)
- —Not posted · NCT00236717
- Topiramate (Topamax Sprinkle)
- —Not reported
50% responder rate
- Topiramate (Qudexy XR)
- 33.9% vs 17.6%+16.3 vs placeboNCT01142193
- Topiramate (Topamax Sprinkle)
- —Not reported
Seizure freedom
- Topiramate (Qudexy XR)
- —Not posted · NCT00236717
- Topiramate (Topamax Sprinkle)
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Topiramate (Topamax Sprinkle): no structured comparison results are available for Epilepsy.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Topiramate (Qudexy XR): 4 of 4 rows · Topiramate (Topamax Sprinkle): 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Topiramate (Qudexy XR) |
|---|---|
| Dropout rate | 16.9% NCT01142193 · Phase 3 · monotherapy · Epilepsy, Focal Onset Seizures · phase 3 |
| Discontinued due to AEs | 9.7% NCT01142193 · Phase 3 · monotherapy · Epilepsy, Focal Onset Seizures · phase 3 |
| Serious AEs | 1.6% NCT01142193 · Phase 3 · monotherapy · Epilepsy, Focal Onset Seizures · phase 3 |
| Most frequent reported AEs | somnolence 12.1% (placebo 2.4%) dizziness 7.3% (placebo 5.6%) paraesthesia 6.5% (placebo 2.4%) NCT01142193 · Phase 3 · monotherapy · Epilepsy, Focal Onset Seizures · phase 3 |
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Topiramate (Qudexy XR)
show 1 more result
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Topiramate (Qudexy XR)'s landscape · Topiramate (Topamax Sprinkle)'s landscape